We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$1.08B
Cap. Flow
+$1.18B
Cap. Flow %
16.06%
Top 10 Hldgs %
55.65%
Holding
321
New
63
Increased
80
Reduced
61
Closed
90

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$101M
2
ICLR icon
Icon
ICLR
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$87.9M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$82.5M
5
GSK icon
GSK
GSK
+$66.7M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$40.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$36.7M
3
SHAK icon
Shake Shack
SHAK
+$32.9M
4
INCY icon
Incyte
INCY
+$30.5M
5
CYTK icon
Cytokinetics
CYTK
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 39.34%
2 Consumer Discretionary 6.39%
3 Consumer Staples 5.37%
4 Technology 5.27%
5 Communication Services 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SKX
76
DELISTED
Skechers
SKX
$19.7M 0.27%
292,633
+15,472
+6% +$1M
ELF icon
77
e.l.f. Beauty
ELF
$5.81B
$19.4M 0.26%
+154,419
New +$18.5M
RIGL icon
78
Rigel Pharmaceuticals
RIGL
$750M
$19.4M 0.26%
1,152,000
-384,000
-25% -$7.36M
NVDA icon
79
NVIDIA
NVDA
$5.42T
$16.7M 0.23%
124,215
-26,469
-18% -$3.65M
ROST icon
80
Ross Stores
ROST
$81.9B
$15.8M 0.22%
104,690
-9,622
-8% -$1.41M
NBIS
81
Nebius Group N.V.
NBIS
$47.7B
$15.5M 0.21%
+560,908
New +$13.7M
CKPT
82
DELISTED
Checkpoint Therapeutics
CKPT
$14.3M 0.19%
4,460,545
+574,545
+15% +$1.95M
NVRO
83
DELISTED
NEVRO CORP.
NVRO
$13.9M 0.19%
3,736,000
+8,000
+0.2% +$36.9K
LOW icon
84
Lowe's Companies
LOW
$125B
$13.6M 0.19%
55,157
+2,122
+4% +$567K
SN icon
85
SharkNinja
SN
$26.1B
$13.4M 0.18%
+137,821
New +$14.1M
EW icon
86
Edwards Lifesciences
EW
$51.7B
$12.6M 0.17%
169,829
+4,834
+3% +$338K
BJRI icon
87
BJ's Restaurants
BJRI
$1.48B
$12.3M 0.17%
350,000
+200,000
+133% +$7.09M
SNN icon
88
Smith & Nephew
SNN
$12.6B
$12.1M 0.17%
494,000
+270,000
+121% +$7.16M
BLTE
89
Belite Bio
BLTE
$6.54B
$10.6M 0.14%
+167,930
New +$11.1M
FL
90
DELISTED
Foot Locker
FL
$10.6M 0.14%
485,000
-170,000
-26% -$3.97M
BILL icon
91
BILL Holdings
BILL
$4.78B
$10.5M 0.14%
124,291
-80,485
-39% -$6M
BABA icon
92
Alibaba
BABA
$308B
$10.5M 0.14%
+124,000
New +$11.7M
TMO icon
93
Thermo Fisher Scientific
TMO
$220B
$10.4M 0.14%
20,044
-12,109
-38% -$6.66M
ULTA icon
94
Ulta Beauty
ULTA
$24.3B
$10.4M 0.14%
23,845
-3,564
-13% -$1.38M
AXGN icon
95
Axogen
AXGN
$2.5B
$10.1M 0.14%
613,000
+212,945
+53% +$3.02M
TSM icon
96
TSMC
TSM
$2.18T
$9.87M 0.13%
50,000
-25,000
-33% -$4.84M
LEVI icon
97
Levi Strauss
LEVI
$9.39B
$9.52M 0.13%
550,000
-520,000
-49% -$9.2M
ILMN icon
98
Illumina
ILMN
$28.4B
$9.37M 0.13%
70,083
+62,955
+883% +$8.97M
CPRI icon
99
Capri Holdings
CPRI
$1.74B
$9.16M 0.13%
+435,000
New +$11.8M
GKOS icon
100
Glaukos
GKOS
$10.6B
$8.83M 0.12%
+58,919
New +$8.12M
2 3
4
5 6

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Armistice Capital held 321 positions worth $7.33B, up 17% from $6.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital deployed $1.18B of net new capital in Q4 2024, opening 63 new positions and adding to 80 existing holdings. Its largest new stake was Exact Sciences: 1,617,000 shares worth $90.9M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $36.7M trimmed.

  • Armistice Capital's largest Q4 2024 buy was Exact Sciences: 1,617,000 shares worth $90.9M.
  • Armistice Capital added most to Neurocrine Biosciences in Q4 2024, an estimated $87.9M increase.
  • Armistice Capital's biggest Q4 2024 reduction was PTC Therapeutics, cutting an estimated $36.7M.
  • Armistice Capital fully exited Alkermes in Q4 2024, selling an estimated $40.5M.
  • Armistice Capital's ten largest holdings make up 56% of its $7.33B portfolio in Q4 2024.
  • Armistice Capital opened 63 new positions and closed 90 in Q4 2024.
  • Armistice Capital's portfolio value rose 17% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.